Inactive Instrument

News Galapagos NV Euronext Bruxelles

Stocks

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles Other stock markets
-	-

06-10	Lakefront Biotherapeutics Kicks Off Up to EUR50 Million Share Buyback Program	MT
06-10	Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program	MT

All News

Mentions Relevance

06-10	Lakefront Biotherapeutics Kicks Off Up to EUR50 Million Share Buyback Program	MT
06-10	Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program	MT
06-10	Lakefront Announces Initiation of €50 Million Stock Repurchase Program	GL
06-09	Lakefront Biotherapeutics Names New Chief Medical Officer	MT
06-09	Lakefront Biotherapeutics Names Eric Hedrick as Chief Medical Officer	MT
06-09	Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer	GL
06-09	Lakefront Biotherapeutics NV Announces Appointment of Eric Hedrick as Chief Medical Officer	CI
06-05	Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline	BU
06-05	GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE	GL
05-27	Lakefront receives transparency notification from Bank of America	RE
05-27	Lakefront Receives Transparency Notification from Bank of America	GL
05-08	Galapagos NV will Change its Name to Lakefront Biotherapeutics	CI
05-08	Galapagos : Anti-Bribery and Anti-Corruption Policy	PU
05-07	Galapagos NV, Q1 2026 Earnings Call, May 07, 2026
05-07	Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update	GL
05-07	Lakefront Biotherapeutics NV Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-29	Galapagos Nv Announces Appointment of Gino Santini as Independent Non-Executive Director	CI
04-29	Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026	GL
04-28	Coultreon Biopharma BV announced that it has received $125 million in funding from a group of investors	CI
04-07	RBC Adjusts Price Target on Galapagos NV to $28 From $33, Maintains Sector Perform Rating	MT
03-31	Galapagos NV, Gilead Sciences, Inc. - M&A Call
03-31	Galapagos, Gilead Sciences Sign Binding Deal for $1.7 Billion Ouro Medicines Acquisition	MT
03-31	Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases	GL
03-27	Galapagos announces nomination of Gino Santini to its board of directors	RE
03-27	Galapagos : GLPG Convening Notice ENG Final2056061.1	PU